🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Ingrid Lilienthal

Karolinska Institutet

ORCID: 0000-0001-5270-7268

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Targeting SAMHD1 with hydroxyurea in first‐line cytarabine‐based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT‐AML trial”.

Targeting SAMHD1 with hydroxyurea in first‐line cytarabine‐based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT‐AML trial

Journal of Internal Medicine(2022)10.1111/joim.13553

N/A

0.442DataRank · unranked

18 citations

Ingrid Lilienthal, Nikolaos Tsesmetzis, Magda Lourda, Sofia Bengtzén, Anna Bohlin +20 more

SOX11 is a novel binding partner and endogenous inhibitor of SAMHD1 ara-CTPase activity in mantle cell lymphoma

Blood(2024)10.1182/blood.2023022241

N/A

0DataRank · unranked

13 citations

Ingrid Lilienthal, Martin Lord, Magali Merrien, Agata M. Wasik, Marta Sureda-Gómez +19 more

Addition of hydroxyurea (hydroxycarbamide) enhances the efficacy of fludarabine/cytarabine‐based salvage regimens against acute myeloid leukaemia

British Journal of Haematology(2025)10.1111/bjh.70180

N/A

0DataRank · unranked

1 citations

Sijia Tao, Christer Nilsson, Elory Leonard, Runqing Zhang, Agnes L. Sorteberg +19 more